Vistagen therapeutics announces positive meeting with fda regarding pivotal phase 3 study of ph94b

Vistagen therapeutics announces positive meeting with fda regarding pivotal phase 3 study of ph94b for acute treatment of anxiety in patients with social anxiety disorder.vistagen therapeutics inc - company reaches consensus with fda on key aspects of novel pivotal phase 3 study.vistagen therapeutics inc - agency guidance may provide significant time- and cost-efficiency for phase 3 program.
VTGN Ratings Summary
VTGN Quant Ranking